Hong Liu

Hong Liu


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2021 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
LTLei Tian
Lei Tian
TQTaotao Qiang
Taotao Qiang
Chengyuan LiangChengyuan Liang
Chengyuan Liang
XRXiaodong Ren
Xiaodong Ren
MJMinyi Jia
Minyi Jia
HLHong Liu
Hong Liu

1 August 2021 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
Chengyuan LiangChengyuan Liang
Chengyuan Liang
GQGuaiping Qiao
Guaiping Qiao
YLYuzhi Liu
Yuzhi Liu
LTLei Tian
Lei Tian
NHNan Hui
Nan Hui
XRXiaodong Ren
Xiaodong Ren

1 May 2021 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
DTDengke Tian
Dengke Tian
YLYuzhi Liu
Yuzhi Liu
Chengyuan LiangChengyuan Liang
Chengyuan Liang
LXLiang Xin
Liang Xin
XXXiaolin Xie
Xiaolin Xie
WCWenqiang Cao
Wenqiang Cao
The SARS-CoV-2 outbreak and pandemic that began near the end of 2019 has posed a challenge to global health. At present, many candidate small-molecule therapeutics have been developed that can inhibit both the infection and replication of SARS-CoV-2 and even potentially relieve cytokine storms and other related complications. Meanwhile, host-targeted drugs that inhibit cellular transmembrane serine protease (TMPRSS2) can prevent SARS-CoV-2 from entering cells, and its combination with chloroquine and dihydroorotate dehydrogenase (DHODH) inhibitors can limit the spread of SARS-CoV-2 and reduce the morbidity and mortality of patients with COVID-19. The present article provides an overview of these small-molecule therapeutics based on insights from medicinal chemistry research and focuses on RNA-dependent RNA polymerase (RdRp) inhibitors, such as the nucleoside analogues remdesivir, favipiravir and ribavirin. This review also covers inhibitors of 3C-like protease (3CLpro), papain-like protease (PLpro) and other potentially innovative active ingredient molecules, describing their potential targets, activities, clinical status and side effects.

1 December 2021 in Phytomedicine
Verified
Journal Article
Closed access
DYDan Yang
Dan Yang
JLJingyi Li
Jingyi Li
Chengyuan LiangChengyuan Liang
Chengyuan Liang
LTLei Tian
Lei Tian
CSChunyang Shi
Chunyang Shi
WCWenqiang Cao
Wenqiang Cao